Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305-5324, USA.
Hum Pathol. 2010 Dec;41(12):1726-34. doi: 10.1016/j.humpath.2010.05.010. Epub 2010 Sep 9.
Recent studies have exploited an antibody directed against programmed death 1 expressed by follicular helper T-cells in the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma. We had previously described clinically relevant, variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma and, in this study, sought to address the diagnostic utility of programmed death 1 in comparison with CD57 in variant nodular lymphocyte predominant Hodgkin lymphoma. Immunohistologic staining for programmed death 1 was carried out on biopsies of 67 patients with variant nodular lymphocyte predominant Hodgkin lymphoma. Thirty-four additional cases of nodular lymphocyte predominant Hodgkin lymphoma with associated diffuse areas, de novo T-cell and histiocyte-rich large B-cell lymphoma, and lymphocyte-rich classic Hodgkin lymphoma were also studied. Our results show that programmed death 1 positivity was found in the majority of nodular lymphocyte predominant Hodgkin lymphoma cases with a classic nodular architecture (87%) as compared with 50% for CD57 and was particularly helpful in identifying extranodular large atypical cells. Nodular lymphocyte predominant Hodgkin lymphoma with diffuse areas showed a gradual decrease in programmed death 1 reactivity from nodular to diffuse areas, although a significant proportion (40%-50%) of cases retained programmed death 1 positivity also in diffuse areas. In addition, T-cell and histiocyte-rich large B-cell lymphoma and lymphocyte-rich classic Hodgkin lymphoma displayed programmed death 1 positivity in a significant subset of cases (33%-40%). In conclusion, our study supports the utility of programmed death 1 in the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma and shows greater sensitivity of staining of programmed death 1 as compared with CD57 across all variants of nodular lymphocyte predominant Hodgkin lymphoma. Loss of programmed death 1 reactivity did not correlate with diffuse areas, progression, or the ability to differentiate nodular lymphocyte predominant Hodgkin lymphoma from T-cell and histiocyte-rich large B-cell lymphoma. These findings suggest the need for continued vigilance in the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma and its immunoarchitectural variants as well as related lymphomas in their differential diagnosis.
最近的研究利用了一种针对滤泡辅助 T 细胞表达的程序性死亡 1 抗体来诊断结节性淋巴细胞为主型霍奇金淋巴瘤。我们之前描述了具有临床意义的、变异的结节性淋巴细胞为主型霍奇金淋巴瘤免疫结构模式,在这项研究中,我们试图比较程序性死亡 1 在变异型结节性淋巴细胞为主型霍奇金淋巴瘤中的诊断效用与 CD57 的比较。对 67 例变异型结节性淋巴细胞为主型霍奇金淋巴瘤的活检进行程序性死亡 1 的免疫组织化学染色。还研究了 34 例伴有弥漫区、新诊断的 T 细胞和组织细胞丰富的大 B 细胞淋巴瘤以及富含淋巴细胞的经典霍奇金淋巴瘤的结节性淋巴细胞为主型霍奇金淋巴瘤病例。我们的结果表明,与 CD57 相比,具有经典结节状结构的大多数结节性淋巴细胞为主型霍奇金淋巴瘤病例中发现程序性死亡 1 阳性(87%),并且特别有助于识别结节外大异型细胞。弥漫区结节性淋巴细胞为主型霍奇金淋巴瘤从结节区到弥漫区程序性死亡 1 反应逐渐降低,但在弥漫区也有相当比例(40%-50%)的病例保留程序性死亡 1 阳性。此外,T 细胞和组织细胞丰富的大 B 细胞淋巴瘤和富含淋巴细胞的经典霍奇金淋巴瘤在相当一部分病例中显示程序性死亡 1 阳性(33%-40%)。总之,我们的研究支持程序性死亡 1 在诊断结节性淋巴细胞为主型霍奇金淋巴瘤中的应用,并显示与 CD57 相比,在所有结节性淋巴细胞为主型霍奇金淋巴瘤变异型中,程序性死亡 1 的染色敏感性更高。程序性死亡 1 反应的丧失与弥漫区、进展或区分结节性淋巴细胞为主型霍奇金淋巴瘤与 T 细胞和组织细胞丰富的大 B 细胞淋巴瘤的能力无关。这些发现表明,在诊断结节性淋巴细胞为主型霍奇金淋巴瘤及其免疫结构变体以及在鉴别诊断中相关淋巴瘤时,需要保持警惕。